太极集团：股东拟实施吸收合并 公司控制权保持稳定

Group 1 - The core point of the announcement is that Taiji Group's shareholder, Chongqing Taiji Medicinal Plant Resources Development Co., Ltd., plans to absorb and merge its wholly-owned subsidiary, Chongqing Fuling Xilan Biotechnology Co., Ltd., with no impact on the company's control and operational independence [1][2] - The merger involves the transfer of shares: Xilan Biotechnology currently holds 11.8953 million unrestricted circulating shares, accounting for 2.157% of the total share capital of Taiji Group, which will be fully inherited by the resources company after the merger [1] - Post-merger, the resources company's shareholding in Taiji Group will increase from 367,300 shares to 12.2626 million shares, raising its ownership percentage from 0.067% to 2.224% [1] Group 2 - The merger does not involve any changes in equity increase or decrease, and the controlling shareholder, Taiji Group Co., Ltd., along with its concerted parties, will maintain a total shareholding of 1.661 billion shares, representing 30.118% [1] - The announcement clarifies that the transaction will not affect the personnel, assets, finances, business, or institutional independence of Taiji Group, and there are no circumstances that would harm the interests of the company and all shareholders [1] - Both the resources company and Xilan Biotechnology are wholly-owned subsidiaries within the Taiji Group system, with the former focusing on traditional Chinese medicine cultivation and research, while the latter is dedicated to the development and research of biopharmaceutical products [2]